Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Research
Molecular Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Rapid Impact Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Metabolism Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Spotlight on Genomic Analysis of Rare and Understudied Cancers
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published August 2015
  • Article
  • Info & Metrics
  • PDF
Loading

SB Screen for Lung Cancer Drivers

Dorr et al. Page 1238

To realize the potential of targeted therapy for lung cancer we need to greatly expand our understanding of the genetic alterations that drive tumor growth. Sleeping Beauty (SB) mutagenesis was used by Dorr and colleagues to probe the genome in an unbiased fashion to uncover genetic drivers of lung cancer. These data will help guide development of novel targeted therapies to bolster our arsenal for combatting the most deadly cancer in the United States. Importantly, this article highlights the finding that alterations in the oxidative response pathway contribute to tumorigenesis. This study suggests that newly developed therapeutic agents that target cellular redox regulation may be effective in treating lung cancer.

Nutlin Cooperates with Genotoxic Agents

Carrillo et al. Page 1197

Ovarian carcinomas frequently inactivate p53, are challenging to treat, and commonly become resistant to standard chemotherapy. Nutlin, a drug designed to restore p53 activity by inhibiting its binding to Mdm2 protein, also increases Mdm2 levels. Carrillo and colleagues show that Nutlin stabilizes Mdm2, resulting in inhibition of DNA damage signaling and delayed DNA break repair mediated by Nbs1 of the Mre11–Nbs1–Rad50 DNA repair complex. When Nutlin was combined with genotoxic agents, a cooperative effect resulted in increased apoptosis of ovarian cancer cells with inactive p53. Thus, pharmacologically increasing Mdm2 levels together with chemotherapy is therapeutically beneficial for treating cancers that lack functional p53.

Functional Promoter Mutations in Melanoma

Poulos et al. Page 1218

The impact of somatic mutations on regulation at gene promoters in cancer has not been systematically evaluated. Poulos and colleagues assessed the influence of promoter mutations on promoter activity in whole-genome sequenced melanoma cells. The study revealed a high number of promoter mutations, many of which significantly altered promoter activity using validation assays. Interestingly, and supporting a potentially pathological role, one mutation within the promoter of the metabolic gene NDUFB9 is recurrent in a subset of melanomas and co-occurs with coding NF1 mutations. This study reveals frequent functional cis-regulatory mutations in cutaneous melanomas, highlighting the need to examine their role in tumorigenesis to find therapeutic targets.

K-Ras Mutations Correlate with CREB Activity

Steven et al. Page 1248

Colorectal cancer is one of the most prevalent cancer types worldwide, and K-Ras mutations are a common feature of this type of cancer. Steven and colleagues identify a significant correlation between K-RasV12 mutation and activation of the transcription factor CREB. Targeting CREB activity with small-molecule inhibitors and by shRNAs reduced the neoplastic properties of the cells. Mechanistically, the in vivo tumorigenicity of the K-RasV12-transformed cells was reduced after CREB silencing, but the altered pattern was dependent on the immunogenicity of the animals. Therefore, CREB represents a promising therapeutic target for colorectal cancer using small-molecule inhibitors alone or in combination with immunotherapy.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Research: 13 (8)
August 2015
Volume 13, Issue 8
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Research
(Your Name) thought you would be interested in this article in Molecular Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Res August 1 2015 (13) (8) 1161;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Res August 1 2015 (13) (8) 1161;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • SB Screen for Lung Cancer Drivers
    • Nutlin Cooperates with Genotoxic Agents
    • Functional Promoter Mutations in Melanoma
    • K-Ras Mutations Correlate with CREB Activity
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Rapid Impact Archive
  • Meeting Abstracts

Information for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCR

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Research
eISSN: 1557-3125
ISSN: 1541-7786

Advertisement